Experienced in Febrile Neutropenia

Ming-shen Dai

TPQ, TW 
Experienced in Febrile Neutropenia
TPQ, TW 
OverviewLocationsClinical Research

Overview

Ming-shen Dai practices in Taiwan. Dai is rated as an Experienced expert by MediFind in the treatment of Febrile Neutropenia. Their top areas of expertise are Triple-Negative Breast Cancer, Breast Cancer, Agranulocytosis, Febrile Neutropenia, and Mastectomy.

Their clinical research consists of co-authoring 75 peer reviewed articles and participating in 4 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 2 articles in the study of Febrile Neutropenia.

Locations

TPQ, Taiwan
Other Locations
Taipei, TNQ, Taiwan
No. 161, Minquan E. Road, Taipei 114, Neihu, TPQ, Taiwan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

4 Clinical Trials

A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Abemaciclib, Standard Adjuvant Endocrine Therapy
Study Phase: Phase 3
A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients
A Clinical Study to Determine the Pharmacokinetics of Oraxol in Breast Cancer Patients
Enrollment Status: Completed
Publish Date: March 12, 2025
Intervention Type: Drug
Study Phase: Phase 1
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
A Phase 1/2 Open-label Study to Investigate the Safety and Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of Modakafusp Alfa (TAK-573) as a Single Agent in Patients With Relapsed Refractory Multiple Myeloma
Enrollment Status: Completed
Publish Date: December 24, 2024
Intervention Type: Drug
Study Drugs: TAK-573, Dexamethasone
Study Phase: Phase 1/Phase 2
A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients
A Safety Study of Oraxol (HM30181 + Oral Paclitaxel) in Cancer Patients
Enrollment Status: Completed
Publish Date: July 29, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 3 Less Clinical Trials

75 Total Publications

Immune checkpoint inhibitor therapy and risk of type 1 diabetes mellitus in metastatic cancer patients.
Immune checkpoint inhibitor therapy and risk of type 1 diabetes mellitus in metastatic cancer patients.
Journal: Diabetology & metabolic syndrome
Published: July 28, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dai's expertise for a condition
ConditionClose
      View All 19 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile